ENGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
enGene Holdings's quarterly additional paid-in capital increased from Jul. 2023 ($7.75 Mil) to Oct. 2023 ($13.72 Mil) and increased from Oct. 2023 ($13.72 Mil) to Jan. 2024 ($14.33 Mil).
enGene Holdings's annual additional paid-in capital increased from Oct. 2021 ($7.59 Mil) to Oct. 2022 ($7.68 Mil) and increased from Oct. 2022 ($7.68 Mil) to Oct. 2023 ($13.72 Mil).
The historical data trend for enGene Holdings's Additional Paid-In Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Holdings Annual Data | |||||||||
Trend | Oct20 | Oct21 | Oct22 | Oct23 | |||||
Additional Paid-In Capital | - | 7.59 | 7.68 | 13.72 |
enGene Holdings Quarterly Data | ||||||||||
Oct20 | Oct21 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Additional Paid-In Capital | Get a 7-Day Free Trial | - | 7.72 | 7.75 | 13.72 | 14.33 |
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
Additional Paid-In Capital | = | (Issue Price | - | Par Value) | * | Shares Outstanding (Diluted Average) |
Thank you for viewing the detailed overview of enGene Holdings's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard M Glickman | director | C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Jason David Hanson | director, officer: Chief Executive Officer | 8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463 |
Lumira Capital Investment Management Inc. | 10 percent owner | 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5 |
Richard Paul Bryce | officer: Chief Medical Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Fonds De Solidarite Des Travailleurs Du Quebec | 10 percent owner | 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4 |
Gerald A Brunk | director | C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142 |
Jasper Bos | director | BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102 |
Grassin Alexandre Jean-rene Erwan | officer: Int. Chief Financial Officer | 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
Anthony Tzeyew Cheung | officer: Chief Technology Officer | 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
Alexander Julian Nichols | officer: Pres. & Chief Operating Ofc. | 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
James Crowley Sullivan | officer: Chief Scientific Officer | 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9 |
Forbion Growth Sponsor Feac I B.v. | 10 percent owner | GOOIMEER 2 35,, NAARDEN P7 1411DC |
Forbion Growth Opportunities Fund I Cooperatief U.a. | 10 percent owner | GOOIMEER 235, 1411 DC, NAARDEN P7 00000 |
Forbion Growth Management B.v. | 10 percent owner | C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807 |
From GuruFocus
By PRNewswire • 12-22-2023
By PRNewswire • 11-29-2023
By PRNewswire • 12-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.